Granite Bio AG
Granite Bio - Model GRT-001 -First-in-class Therapeutic Antibodies
FromGranite Bio AG
Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.
Novel Mode of Action: Depletion of pathogenic pro-inflammatory monocytes via ADCC/ADCP. First-in-class »Innate Rituximab«.